Adicet Bio, Inc. (0HX7.L)
- Previous Close
2.1750 - Open
1.9800 - Bid --
- Ask --
- Day's Range
1.9189 - 1.9800 - 52 Week Range
1.1020 - 7.6000 - Volume
2,132 - Avg. Volume
6,355 - Market Cap (intraday)
989,207 - Beta (5Y Monthly) 1.62
- PE Ratio (TTM)
-- - EPS (TTM)
-1.0490 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.
www.adicetbio.com143
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Recent News: 0HX7.L
Performance Overview: 0HX7.L
Trailing total returns as of 4/20/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0HX7.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0HX7.L
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-30.80%
Return on Equity (ttm)
-61.69%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-142.66M
Diluted EPS (ttm)
-1.0490
Balance Sheet and Cash Flow
Total Cash (mrq)
159.71M
Total Debt/Equity (mrq)
12.30%
Levered Free Cash Flow (ttm)
-61.28M